<p>Lifecore Biomedical（納斯達克：LFCR - 獲取免費報告）可能將在 2026 年 1 月 1 日星期四市場收盤後發佈其 2026 年第二季度財報。分析師預計 Lifecore Biomedical 本季度每股收益為（$0.11），收入為 3530.80 萬美元。有興趣的人可以在公司即將發佈的 2026 年第二季度財報頁面找到電話會議的詳細信息，最新的電話會議安排在 2026 年 1 月 2 日星期五東部時間凌晨 12:00。</p>
<p>獲取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
<p>Lifecore Biomedical（納斯達克：LFCR - 獲取免費報告）上一次發佈季度財報是在 4 月 1 日星期一。該公司報告本季度每股收益（EPS）為（$0.22）。Lifecore Biomedical 的股本回報率為負的 1211.09%，淨利潤率為負的 25.59%。該公司本季度的收入為 2654 萬美元。分析師平均預計 Lifecore Biomedical 在當前財政年度的每股收益為-$1，下一財政年度的每股收益也為-$1。</p>
<h2>Lifecore Biomedical 股票表現</h2>
<p>納斯達克：LFCR 在星期四開盤價為$8.24。該公司的市值為 3.0875 億美元，市盈率為-7.70，貝塔值為 0.60。該公司的 50 日簡單移動平均為$7.48，200 日簡單移動平均為$7.45。該公司的債務與股本比率為 113.76，流動比率為 2.80，速動比率為 1.67。Lifecore Biomedical 的 1 年最低價為$4.76，1 年最高價為$8.85。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票研究分析師對該股票發表了評論。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Lifecore Biomedical 股票的 “賣出（d）” 評級。KeyCorp 在 9 月 3 日星期三的研究報告中開始覆蓋 Lifecore Biomedical 的股票。他們對該公司的評級為 “行業權重”。一位投資分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Lifecore Biomedical 目前的共識評級為 “持有”，平均目標價為$6.00。</p>
<p><strong>閲讀我們關於 Lifecore Biomedical 的最新報告</strong></p>
<h2>機構投資者對 Lifecore Biomedical 的看法</h2>
<p>對沖基金最近增加或減少了在該公司的股份。Quarry LP 在第三季度購買了價值$28,000 的 Lifecore Biomedical 新股份。BNP Paribas 金融市場在第三季度將其在 Lifecore Biomedical 的股份增加了 92.7%。BNP Paribas 金融市場現在擁有 5791 股該公司的股票，價值$43,000，此前在上個季度又購買了 2786 股。懷俄明州購買了價值約$69,000 的 Lifecore Biomedical 新股份。製造商人壽保險公司在第二季度購買了價值$88,000 的 Lifecore Biomedical 新股份。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Lifecore Biomedical 的持股增加了 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 14785 股該公司的股票，價值$104,000，此前在上個季度又購買了 1886 股。機構投資者持有該公司 83.36% 的股份。</p>
<h2>Lifecore Biomedical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Lifecore Biomedical, Inc 是一家公開交易的專業生物製藥公司，總部位於明尼蘇達州查斯卡。該公司專注於開發、製造和商業化基於透明質酸（HA）的產品，以滿足醫療和美容需求。Lifecore 的專有 HA 配方旨在滿足高度監管市場對純度、一致性和性能的嚴格監管標準。</p>
<p>該公司的產品組合涵蓋多個治療領域，包括眼科、骨科、皮膚科和傷口護理。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Lifecore Biomedical 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤前一個月</li>
<li>麥當勞的秘密</li>
<li>家族信託如何幫助保護您的財富</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 在 Lifecore Biomedical 嗎？</h2>
<p>在您考慮 Lifecore Biomedical 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Lifecore Biomedical 並不在名單上。</p>
<p>雖然 Lifecore Biomedical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LFCR

<p>Lifecore Biomedical（納斯達克代碼：LFCR）將在 1 月 1 日市場收盤後發佈 2026 年第二季度財報。分析師預計每股收益為（$0.11），收入為 3530.8 萬美元。該公司之前報告的每股收益為（$0.22），收入為 2654 萬美元。Lifecore 的股票開盤價為$8.24，市值為 3.0875 億美元。分析師給予該股票的共識評級為 “持有”，平均目標價為$6.00。機構投資者持有該股票的 83.36%</p>

<p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, January 1st. Analysts expect Lifecore Biomedical to post earnings of ($0.11) per share and revenue of $35.3080 million for the quarter. Interested persons can find conference call details on the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, January 2, 2026 at 12:00 AM ET.</p>
<div class="lb-trans"><p>Lifecore Biomedical（納斯達克：LFCR - 獲取免費報告）可能將在 2026 年 1 月 1 日星期四市場收盤後發佈其 2026 年第二季度財報。分析師預計 Lifecore Biomedical 本季度每股收益為（$0.11），收入為 3530.80 萬美元。有興趣的人可以在公司即將發佈的 2026 年第二季度財報頁面找到電話會議的詳細信息，最新的電話會議安排在 2026 年 1 月 2 日星期五東部時間凌晨 12:00。</p>
</div><p>Get <strong>Lifecore Biomedical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
</div><p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.22) earnings per share (EPS) for the quarter. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 25.59%.The company had revenue of $26.54 million for the quarter. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Lifecore Biomedical（納斯達克：LFCR - 獲取免費報告）上一次發佈季度財報是在 4 月 1 日星期一。該公司報告本季度每股收益（EPS）為（$0.22）。Lifecore Biomedical 的股本回報率為負的 1211.09%，淨利潤率為負的 25.59%。該公司本季度的收入為 2654 萬美元。分析師平均預計 Lifecore Biomedical 在當前財政年度的每股收益為-$1，下一財政年度的每股收益也為-$1。</p>
</div><h2>Lifecore Biomedical Stock Performance</h2>
<div class="lb-trans"><h2>Lifecore Biomedical 股票表現</h2>
</div><p>NASDAQ:LFCR opened at $8.24 on Thursday. The company has a market capitalization of $308.75 million, a P/E ratio of -7.70 and a beta of 0.60. The business has a fifty day simple moving average of $7.48 and a two-hundred day simple moving average of $7.45. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a 1 year low of $4.76 and a 1 year high of $8.85.</p>
<div class="lb-trans"><p>納斯達克：LFCR 在星期四開盤價為$8.24。該公司的市值為 3.0875 億美元，市盈率為-7.70，貝塔值為 0.60。該公司的 50 日簡單移動平均為$7.48，200 日簡單移動平均為$7.45。該公司的債務與股本比率為 113.76，流動比率為 2.80，速動比率為 1.67。Lifecore Biomedical 的 1 年最低價為$4.76，1 年最高價為$8.85。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Lifecore Biomedical in a report on Wednesday, October 8th. KeyCorp assumed coverage on shares of Lifecore Biomedical in a research note on Wednesday, September 3rd. They issued a &#34;sector weight&#34; rating for the company. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lifecore Biomedical currently has a consensus rating of &#34;Hold&#34; and an average price target of $6.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師對該股票發表了評論。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Lifecore Biomedical 股票的 “賣出（d）” 評級。KeyCorp 在 9 月 3 日星期三的研究報告中開始覆蓋 Lifecore Biomedical 的股票。他們對該公司的評級為 “行業權重”。一位投資分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Lifecore Biomedical 目前的共識評級為 “持有”，平均目標價為$6.00。</p>
</div><p><strong>Read Our Latest Report on Lifecore Biomedical</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Lifecore Biomedical 的最新報告</strong></p>
</div><h2>Institutional Investors Weigh In On Lifecore Biomedical</h2>
<div class="lb-trans"><h2>機構投資者對 Lifecore Biomedical 的看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in Lifecore Biomedical during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its stake in Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock worth $43,000 after purchasing an additional 2,786 shares in the last quarter. State of Wyoming bought a new position in shares of Lifecore Biomedical in the second quarter worth approximately $69,000. The Manufacturers Life Insurance Company purchased a new stake in Lifecore Biomedical during the 2nd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after buying an additional 1,886 shares in the last quarter. Institutional investors own 83.36% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近增加或減少了在該公司的股份。Quarry LP 在第三季度購買了價值$28,000 的 Lifecore Biomedical 新股份。BNP Paribas 金融市場在第三季度將其在 Lifecore Biomedical 的股份增加了 92.7%。BNP Paribas 金融市場現在擁有 5791 股該公司的股票，價值$43,000，此前在上個季度又購買了 2786 股。懷俄明州購買了價值約$69,000 的 Lifecore Biomedical 新股份。製造商人壽保險公司在第二季度購買了價值$88,000 的 Lifecore Biomedical 新股份。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Lifecore Biomedical 的持股增加了 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 14785 股該公司的股票，價值$104,000，此前在上個季度又購買了 1886 股。機構投資者持有該公司 83.36% 的股份。</p>
</div><h2>Lifecore Biomedical Company Profile</h2>
<div class="lb-trans"><h2>Lifecore Biomedical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.</p>
<div class="lb-trans"><p>Lifecore Biomedical, Inc 是一家公開交易的專業生物製藥公司，總部位於明尼蘇達州查斯卡。該公司專注於開發、製造和商業化基於透明質酸（HA）的產品，以滿足醫療和美容需求。Lifecore 的專有 HA 配方旨在滿足高度監管市場對純度、一致性和性能的嚴格監管標準。</p>
</div><p>The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.</p>
<div class="lb-trans"><p>該公司的產品組合涵蓋多個治療領域，包括眼科、骨科、皮膚科和傷口護理。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Lifecore Biomedical</li>
<li>Do not delete, read immediately</li>
<li>A month before the crash</li>
<li>The McDonald's Secret</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Lifecore Biomedical 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤前一個月</li>
<li>麥當勞的秘密</li>
<li>家族信託如何幫助保護您的財富</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lifecore Biomedical Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 在 Lifecore Biomedical 嗎？</h2>
</div><p>Before you consider Lifecore Biomedical, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Lifecore Biomedical 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Lifecore Biomedical 並不在名單上。</p>
</div><p>While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lifecore Biomedical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lifecore Biomedical (LFCR) 預計將在週四發佈季度財報